Sentinel Lymph Node Biopsy Provides no Benefit for Stage Zero Breast Cancer, Yale School of Public Health Study Finds
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS), gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.
HEALTH NOTES: Black and Hispanic Cancer Patients Are Underrepresented in Clinical Trials
A new study has shown that clinical trials for new cancer medications rarely analyze data on safety and effectiveness by race and that black and Hispanic patients are consistently underrepresented among participants.
Improving Breast Cancer Outcomes for African Women
For eight days in early June, Melissa Durand, MD, volunteered at the second-largest teaching hospital in Ghana, West Africa. Decades earlier, mammography technologist Judith Abaidoo of Yale New Haven Hospital’s Shoreline Medical Center became one of the first women to perform mammograms in Ghana, where the five-year breast cancer survival rate is estimated to be only 25%.
More women in U.S. receive 3-D mammography but disparities remain
Use of 3-D mammography, an advanced form of breast cancer screening, has risen rapidly in recent years, according to Yale Cancer Center researchers in a new study. But adoption of the technology varies widely, reflecting emerging disparities in care, they said.
Better Science, Better Lives: Women's Health Research at Yale is Working for You
Across the country, it’s becoming clearer every day: We must study the health of women. We must study the influence of sex-and-gender differences on health. And it’s time for all aspects of medical research and practice to embrace this change.
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
New Study in JNCCN Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40
A new study from the Stanford Cancer Institute finds that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive tumor (pathologic complete response). “By assessing patient outcomes in a relatively large group of women under 40 treated with neoadjuvant chemotherapy, this study adds significantly to the existing literature,” said Meena S. Moran, MD, Professor and Director of Yale Radiation Therapy Breast Program, Yale Cancer Center/Smilow Cancer Hospital, Member, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Breast Cancer.
Breast cancer care in U.S. territories lags behind care in states
Older women residing in the U.S territories are less likely to receive recommended or timely care for breast cancer compared with similar women residing in the continental United States, according to Yale researchers. Their findings were published in the March issue of Health Affairs.
Breast cancer breakthrough may have been found in Connecticut
A big breakthrough in the battle against breast cancer may have been found in Connecticut. The discovery was make by a local researcher and helped by a grant from the Terri Brodeur Breast Cancer Foundation with money raised by the Southern Connecticut Breast Cancer Walk. It starts with hundreds of walkers every fall and ends in a lab. The local fight against breast cancer is spearheaded by the foundation. "I feel like a lot of us clinicians have insight into what's going on with the disease type but it's very hard to compete with people who are doing research full time," said Dr. Erin Hofstatter, Yale Cancer Center. "Terri Brodeur has been valuable in giving me a chance."
Yale’s advance in breast cancer surgery to be tested in nationwide study
Removing a small amount of extra tissue around a breast cancer tumor may keep a patient from having a recurrence of the cancer or of having to return to the operating table because not all of the malignant cells were removed in the first operation. That’s the theory that’s being tested in a nationwide clinical trial sponsored by the Yale Cancer Center called SHAVE2. Dr. Anees Chagpar, assistant director of global oncology at the Yale School of Medicine and former director of the Breast Center, is the principal investigator. Chagpar oversaw the first SHAVE trial at Yale, which involved 235 patients with stage 0 to stage 3 breast cancer who were given a partial mastectomy, also known as a lumpectomy. Some were given normal lumpectomies, while others had more tissue removed from around the tumor site, known as cavity shave margins.
Yale enhances its cytometry capabilities
The methods and equipment used to probe cellular questions are rapidly advancing—including, at Yale, through the addition in 2014 of CyTOF, or Cytometry Time-Of-Flight, and this past June of the CyTOF Imaging Mass Cytometer (IMC), which greatly expands Yale's ability to examine specimens that are analyzed both for clinical diagnosis and for basic research.